Brand and Other Names:Vidaza
Dosing & Uses
Dosage Forms & Strengths
powder for injection
May increase 100 mg/m² if no benefit after 2 treatment cycles and no toxicity (other than nausea/vomiting)
Monitor: CBC, hematologic responses, renal toxicity
Acute Myeloid Leukemia (Orphan)
Orphan indication sponsor
- Celgene Corporation; 9900 W. 109th Street, Suite 300; Overland Park, KS 66210
Inj site erythema (35%)
Injection site pain (22.7%)
Pain in limb (20%)
Edema peripheral (18.6%)
Back pain (18.6%)
Chest pain (16.4%)
Febrile neutropenia (16.4%)
Wt loss (15.9%)
Abd pain (15.5%)
Pitting edema (14.5%)
Skin lesion (14.5%)
Dyspnea exertional (14.1%)
Inj site bruising (14.1%)
Appetite decr (12.7%)
Fatigue aggravated (12.7%)
Abd tenderness (11.8%)
Productive cough (11.4%)
Abd pain upper (10.5%)
Crackles lung (10.5%)
Sweating incr (10.5%)
Cardiac murmur (10%)
Gingival bleeding (9.5%)
Injection site pruritus (6.8%)
Postprocedural hemorrhage (5.9%)
Loose stools (5.5%)
Chest wall pain (5%)
Dry skin (5%)
Injection site granuloma/swelling (5%)
Injection site pigmentation change (5%)
Mouth hemorrhage (5%)
Skin nodule (5%)
Interstitial lung disease
Tumor lysis syndrome
Injection site necrosis
Sweet’s syndrome (acute febrile neutrophilic dermatosis)
Necrotizing fasciitis (including fatal cases)
Hypersensitivity to azacitidine or mannitol
Advanced malignant hepatic tumors
Should not get pregnant/father children while on this drug
Renal tubular acidosis, and renal failure reported
Thrombocytopenia, neutropenia, and anemia are common occurrence
Thoroughly monitor hematologic responses
Pregnancy & Lactation
Pregnancy Category: D
Lactation: It is not known whether azacitidine or its metabolites are excreted in milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into consideration the importance of the drug to the mother.
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Hypomethylation of DNA and direct cytotoxic effect on abnl hematopoietic cells in bone marrow
Peak Plasma Concentration: 350-1150 ng/mL
Peak PlasmaTime: 0.5 hr
Vd: 76 ± 26 L
Half-Life: 4 hr
Excretion: primarily in urine (50-85%); feces (minor)
Dextrose 5% solns, Hespan, bicarbonate-containing solns
Reconstitute each vial with 10 mL SWI.
Vigorously shake or roll the vial until all solids are dissolved & clear. The resulting solution will contain azacitidine 10 mg/mL.
Withdraw the required amount & inject into a 50-100 mL infusion bag of either NS or LR
Infuse over 10-40 min
Infusion should be completed within 1 hr of reconstitution
100 mg lyophilized powder reconstituted with 4 mL SWI
Contents of syringe must be resuspended by inverting syringe 2-3x & gently rolling syringe between palms for 30 sec immediately prior to administration
4 mL dose should be equally divided into 2 syringes & injected into 2 separate sites; rotate sites for each injection
May be stored for 1 hr at room temp & up to 8 hr in fridge
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs